Literature DB >> 16763205

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.

Devi K Banerjee1, Madhav V Dhodapkar, Elyana Matayeva, Ralph M Steinman, Kavita M Dhodapkar.   

Abstract

CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg's) play an important role in the maintenance of immune tolerance. The mechanisms controlling the induction and maintenance of Treg's in humans need to be defined. We find that human myeloid dendritic cells (DCs) are superior to other antigen presenting cells for the maintenance of FOXP3(+) Treg's in culture. Coculture of DCs with autologous T cells leads to an increase in both the number of Treg's, as well as the expression of FOXP3 protein per cell both in healthy donors and myeloma patients. DC-mediated expansion of FOXP3(high) Treg's is enhanced by endogenous but not exogenous interleukin-2 (IL-2), and DC-T-cell contact, including the CD80/CD86 membrane costimulatory molecules. DCs also stimulate the formation of Treg's from CD25(-) T cells. The efficacy of induction of Treg's by DCs depends on the nature of the DC maturation stimulus, with inflammatory cytokine-treated DCs (Cyt-DCs) being the most effective Treg inducers. DC-induced Treg's from both healthy donors and patients with myeloma are functional and effectively suppress T-cell responses. A single injection of cytokine-matured DCs led to rapid enhancement of FOXP3(+) Treg's in vivo in 3 of 3 myeloma patients. These data reveal a role for DCs in increasing the number of functional FOXP3(high) Treg's in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763205      PMCID: PMC1895594          DOI: 10.1182/blood-2006-03-011353

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.

Authors:  Aihong Liu; Peisheng Hu; Leslie A Khawli; Alan L Epstein
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

2.  Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction.

Authors:  Sayuri Yamazaki; Munjal Patel; Alice Harper; Anthony Bonito; Hidehiro Fukuyama; Maggi Pack; Kristin V Tarbell; Mia Talmor; Jeffrey V Ravetch; Kayo Inaba; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-10       Impact factor: 11.205

3.  In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.

Authors:  Marc Beyer; Matthias Kochanek; Thomas Giese; Elmar Endl; Martin R Weihrauch; Percy A Knolle; Sabine Classen; Joachim L Schultze
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

4.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

Authors:  Jens Dannull; Zhen Su; David Rizzieri; Benjamin K Yang; Doris Coleman; Donna Yancey; Aijing Zhang; Philipp Dahm; Nelson Chao; Eli Gilboa; Johannes Vieweg
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

5.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

Authors:  Mojgan Ahmadzadeh; Steven A Rosenberg
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

6.  Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

Authors:  Gang Zhou; Charles G Drake; Hyam I Levitsky
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

7.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Authors:  B Salomon; D J Lenschow; L Rhee; N Ashourian; B Singh; A Sharpe; J A Bluestone
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

Review 8.  Immune regulation in tumor-bearing hosts.

Authors:  Clare Baecher-Allan; David E Anderson
Journal:  Curr Opin Immunol       Date:  2006-02-07       Impact factor: 7.486

Review 9.  FOXP3: of mice and men.

Authors:  Steven F Ziegler
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

10.  Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells.

Authors:  H Jonuleit; E Schmitt; G Schuler; J Knop; A H Enk
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

View more
  118 in total

1.  Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients.

Authors:  Sergiusz Markowicz; Zbigniew I Nowecki; Piotr Rutkowski; Andrzej W Lipkowski; Marzena Biernacka; Anna Jakubowska-Mucka; Tomasz Switaj; Aleksandra Misicka; Henryk Skurzak; Hanna Polowniak-Pracka; Jan Walewski
Journal:  Med Oncol       Date:  2012-12       Impact factor: 3.064

2.  Differences in T-helper polarizing capability between human monocyte-derived dendritic cells and monocyte-derived Langerhans'-like cells.

Authors:  Ivan Rajkovic; Ana Dragicevic; Sasa Vasilijic; Biljana Bozic; Tanja Dzopalic; Sergej Tomic; Ivana Majstorovic; Dragana Vucevic; Jelena Djokic; Bela Balint; Miodrag Colic
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

3.  Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.

Authors:  Camilo E Fadul; Jan L Fisher; Thomas H Hampton; Enrico C Lallana; Zhongze Li; Jiang Gui; Zbigniew M Szczepiorkowski; Tor D Tosteson; C Harker Rhodes; Heather A Wishart; Lionel D Lewis; Marc S Ernstoff
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

Review 4.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 5.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 6.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 7.  Dendritic cell modulation as a new interventional approach for the treatment of asthma.

Authors:  Vincent Lombardi; Omid Akbari
Journal:  Drug News Perspect       Date:  2009-10

8.  Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.

Authors:  Kavita M Dhodapkar; Scott Barbuto; Phillip Matthews; Anjli Kukreja; Amitabha Mazumder; David Vesole; Sundar Jagannath; Madhav V Dhodapkar
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

Review 9.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

Review 10.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.